Who
Charles W. Newhall III
Director
Company insider
Files Form 4 as: Director and 10% owner, Supernus Pharmaceuticals; Director, Vitae Pharmaceuticals; 10% owner, Workday; 10% owner, Fusion-Io; 10% owner, Hyperion Therapeutics; Director and 10% owner, Pharmos; 10% owner, Innerworkings; 10% owner, Amicus Therapeutics.
In numbers
- Trades disclosed
- 405
- Buys
- 86
- Sells
- 16
- Bought
- $68.0M
- Sold
- $57.8M
- Companies
- 20
- Companies where not an officer
- 20
- First trade
- 1 Feb 2006
- Last trade
- 24 Feb 2026
- Last filed
- 25 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 21 Nov 2025filed 24 Nov 2025 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 21 Nov 2025filed 24 Nov 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $195K15,000 at $12.98 | filing |
| 9 Oct 2025filed 10 Oct 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.2M23,800 at $50.73 | filing |
| 9 Oct 2025filed 10 Oct 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $62K1,200 at $51.55 | filing |
| 27 Aug 2025filed 29 Aug 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $161K3,588 at $45.01 | filing |
| 25 Aug 2025filed 27 Aug 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $45K1,000 at $45.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $64K1,412 at $45.00 | filing |
| 22 Feb 2025filed 24 Feb 2025 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —5,369 at $0.00 | filing |
| 22 Feb 2025filed 24 Feb 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,369 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,296 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 11 Nov 2024filed 12 Nov 2024 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
News
Gyre Therapeutics (NASDAQ:GYRE) vs. GSK (NYSE:GSK) Head-To-Head ContrastGYRE · dailypolitical.com · 19 Oct 2026Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026GSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGYRE · themarketsdaily.com · 15 Oct 2026Contrasting Scienture (NASDAQ:SCNX) & Gyre Therapeutics (NASDAQ:GYRE)GYRE · themarketsdaily.com · 13 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Charles W. Newhall III; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.